Literature DB >> 24852359

HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1.

Joao Seda Neto1, Katia M R Leite, Adriana Porta, Eduardo A Fonseca, Flavia H Feier, Renata Pugliese, Irene K Miura, Paulo Chapchap, Gilda Porta.   

Abstract

BACKGROUND: Untreated tyrosinemia type 1 (HT1) is manifested by liver failure associated with renal tubular dysfunction, growth failure, and rickets. The indication for liver transplantation (LT) is restricted to non-responders to 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione (NTBC) treatment, patients not treated with NTBC or for patients with HCC. The aim of this study is to report on a series of NTBC naive HT1 patients submitted to LT along with the prevalence of HCC in their liver explants. PROCEDURE: This is a retrospective study of 16 children with HT1 who underwent liver transplantation between January 1993 and December 2012. CLINICAL FEATURES: liver failure in 12 (75%), growth failure in 4 (25%), rickets in 5 (31.2%), hypertrophic cardiomyopathy in three (18.7%), and renal tubulopathy in seven patients (43.7%). Median AFP level was 64,335 ng/ml. Abdominal CT scans showed multiple nodules in most patients. Histopathology of the explants showed cirrhosis in all patients and HCC in 12 (75%), 3 with microvascular invasion. The majority of the tumors were well differentiated. Patient survival rate was 86% at a median follow-up of 6.6 years. All survivors were tumor-free with no adjuvant chemotherapy.
CONCLUSION: In countries where neonatal screening programs are not effective and NTBC treatment is not widely available, LT still plays an important role in the treatment of children with HT1. An early indication in patients who present with multinodular livers can also serve to treat an otherwise underdiagnosed HCC condition.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  children; hepatocellular carcinoma; liver transplantation; outcomes; tyrosinemia

Mesh:

Substances:

Year:  2014        PMID: 24852359     DOI: 10.1002/pbc.25094

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  10 in total

1.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

2.  Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients.

Authors:  Ayse Cigdem Aktuglu Zeybek; Ertugrul Kiykim; Salim Neselioglu; Halise Zeynep Iscan; Tanyel Zubarioglu; Mehmet Serif Cansever; Ozcan Erel
Journal:  Pediatr Res       Date:  2021-10-09       Impact factor: 3.953

Review 3.  Neurometabolic diseases of childhood.

Authors:  Zoltan Patay; Susan I Blaser; Andrea Poretti; Thierry A G M Huisman
Journal:  Pediatr Radiol       Date:  2015-09-07

Review 4.  Liver tumors in children with metabolic disorders.

Authors:  Deborah A Schady; Angshumoy Roy; Milton J Finegold
Journal:  Transl Pediatr       Date:  2015-10

Review 5.  Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

Authors:  Saranya Chidambaranathan-Reghupaty; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2020-11-28       Impact factor: 6.242

6.  Pediatric liver transplantation for hepatocellular cancer and rare liver malignancies: US multicenter and single-center experience (1981-2015).

Authors:  Rohan Vinayak; Ruy J Cruz; Sarangarajan Ranganathan; Ravi Mohanka; George Mazariegos; Kyle Soltys; Geoff Bond; Sameh Tadros; Abhinav Humar; J Wallis Marsh; Robert R Selby; Jorge Reyes; Qing Sun; Kimberly Haberman; Rakesh Sindhi
Journal:  Liver Transpl       Date:  2017-12       Impact factor: 5.799

Review 7.  Liver Transplantation for Pediatric Hepatocellular Carcinoma: A Systematic Review.

Authors:  Christos D Kakos; Ioannis A Ziogas; Charikleia D Demiri; Stepan M Esagian; Konstantinos P Economopoulos; Dimitrios Moris; Georgios Tsoulfas; Sophoclis P Alexopoulos
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.575

8.  In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions.

Authors:  Clara T Nicolas; Caitlin J VanLith; Raymond D Hickey; Zeji Du; Lori G Hillin; Rebekah M Guthman; William J Cao; Benjamin Haugo; Annika Lillegard; Diya Roy; Aditya Bhagwate; Daniel O'Brien; Jean-Pierre Kocher; Robert A Kaiser; Stephen J Russell; Joseph B Lillegard
Journal:  Nat Commun       Date:  2022-08-25       Impact factor: 17.694

Review 9.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

Review 10.  Pediatric hepatocellular carcinoma.

Authors:  Rajeev Khanna; Sanjeev Kumar Verma
Journal:  World J Gastroenterol       Date:  2018-09-21       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.